Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02608710 · ClinicalTrials.gov registry record · Phase 1
RDEA3170 PK/PD Study
A Phase 1 study, sponsored by Ardea Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT02608710: Completed Phase 1 study, sponsored by Ardea Biosciences.
NCT02608710 is a Phase 1 study that has completed, run by Ardea Biosciences. The registered enrollment target is 40 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02608710, a Phase 1 study, has completed, sponsored by Ardea Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the pharmacokinetic and pharmacodynamic effect of RDEA3170 when given as single or multiple doses
Primary Outcome
Single-dose Pharmacokinetic (PK) profile of RDEA3170 4.5 mg, 6 mg and 12 mg
Interventions
- DRUG RDEA3170 4.5 mg
- DRUG RDEA3170 6 mg
- DRUG RDEA3170 12 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2015-11 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
What the finished NCT02608710 record still lists
NCT02608710 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower).
The record links to 0 conditions, and to 3 interventions - of which RDEA3170 4.5 mg is the first listed.
NCT02608710 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02608710 about?
NCT02608710 is a clinical study titled "RDEA3170 PK/PD Study". The purpose of this study is to examine the pharmacokinetic and pharmacodynamic effect of RDEA3170 when given as single or multiple doses
What is the current status of trial NCT02608710?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2015-11. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02608710?
The interventions under investigation include: RDEA3170 4.5 mg (DRUG), RDEA3170 6 mg (DRUG), RDEA3170 12 mg (DRUG).
Who is sponsoring clinical trial NCT02608710?
This trial is sponsored by Ardea Biosciences, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02608710's enrollment target sits among peer trials
40 1130th of 2000 higher than 810 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia